# 2026-07423: Public Input Requested on Orphan Drug Information Collection

2026-07423, Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16, effective Either electronic or written comments on the collection of information must be submitted by June 15, 2026. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07423
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07423
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20460
- Published: 2026-04-16
- Effective: Either electronic or written comments on the collection of information must be submitted by June 15, 2026.
- Comments close: 2026-06-15
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Public Input Requested on Orphan Drug Information Collection

## Summary

The FDA wants your thoughts on how it collects info about orphan drugs—special medicines for rare diseases. They’re asking for comments by June 15, 2026, to keep things clear and easy for drug makers and patients. This helps the FDA improve its paperwork without costing extra time or money for those involved.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with orphan drug requirements.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-07423 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07423/agency-information-collection-activities-proposed-collection-comment-request-orphan-drugs)
- [2026-07423 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07423.pdf)

## Related
- [Previous: 2026-07422, Determination of Regulatory Review Period for Purposes of Patent Extension; UNL…](https://policyrisk.com/federal-register/2026-07422)
- [Next: 2026-07424, Sunshine Act Meetings](https://policyrisk.com/federal-register/2026-07424)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07423 (as of 2026-06-08).
